Zhejiang Dayang Biotech Group Co (003017) - Net Assets
Based on the latest financial reports, Zhejiang Dayang Biotech Group Co (003017) has net assets worth CN¥1.17 Billion CNY (≈ $171.53 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.88 Billion ≈ $274.95 Million USD) and total liabilities (CN¥706.73 Million ≈ $103.42 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 003017 total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.17 Billion |
| % of Total Assets | 62.39% |
| Annual Growth Rate | 16.21% |
| 5-Year Change | 14.74% |
| 10-Year Change | 395.64% |
| Growth Volatility | 25.86 |
Zhejiang Dayang Biotech Group Co - Net Assets Trend (2013–2025)
This chart illustrates how Zhejiang Dayang Biotech Group Co's net assets have evolved over time, based on quarterly financial data. Check 003017 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Zhejiang Dayang Biotech Group Co (2013–2025)
The table below shows the annual net assets of Zhejiang Dayang Biotech Group Co from 2013 to 2025. For live valuation and market cap data, see Zhejiang Dayang Biotech Group Co market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.14 Billion ≈ $166.34 Million |
+7.94% |
| 2024-12-31 | CN¥1.05 Billion ≈ $154.11 Million |
+4.46% |
| 2023-12-31 | CN¥1.01 Billion ≈ $147.53 Million |
+2.35% |
| 2022-12-31 | CN¥985.05 Million ≈ $144.14 Million |
-0.57% |
| 2021-12-31 | CN¥990.71 Million ≈ $144.97 Million |
+3.40% |
| 2020-12-31 | CN¥958.13 Million ≈ $140.20 Million |
+92.36% |
| 2019-12-31 | CN¥498.09 Million ≈ $72.89 Million |
+13.04% |
| 2018-12-31 | CN¥440.62 Million ≈ $64.48 Million |
+30.47% |
| 2017-12-31 | CN¥337.71 Million ≈ $49.42 Million |
+47.25% |
| 2016-12-31 | CN¥229.35 Million ≈ $33.56 Million |
+9.34% |
| 2015-12-31 | CN¥209.76 Million ≈ $30.70 Million |
+6.55% |
| 2014-12-31 | CN¥196.87 Million ≈ $28.81 Million |
+5.04% |
| 2013-12-31 | CN¥187.42 Million ≈ $27.43 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Dayang Biotech Group Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 625.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥462.96 Million | 40.91% |
| Other Components | CN¥668.69 Million | 59.09% |
| Total Equity | CN¥1.13 Billion | 100.00% |
Zhejiang Dayang Biotech Group Co Competitors by Market Cap
The table below lists competitors of Zhejiang Dayang Biotech Group Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Deva Holding AS
IS:DEVA
|
$312.70 Million |
|
Qingdao Victall Railway Co Ltd
SHG:605001
|
$312.75 Million |
|
SOLiD Inc
KQ:050890
|
$312.88 Million |
|
Guangdong Jushen Logistics Co Ltd
SHE:001202
|
$312.95 Million |
|
Precious Shipping Public Company Limited
BK:PSL-R
|
$312.37 Million |
|
Oponeo.pl SA
WAR:OPN
|
$312.32 Million |
|
Seah Holdings
KO:058650
|
$312.31 Million |
|
Nalwa Sons Investments Limited
NSE:NSIL
|
$312.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Dayang Biotech Group Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,052,160,614 to 1,131,642,826, a change of 79,482,212 (7.6%).
- Net income of 99,854,406 contributed positively to equity growth.
- Dividend payments of 54,655,503 reduced retained earnings.
- Other comprehensive income decreased equity by 55,650,061.
- Other factors increased equity by 89,933,370.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥99.85 Million | +8.82% |
| Dividends Paid | CN¥54.66 Million | -4.83% |
| Other Comprehensive Income | CN¥-55.65 Million | -4.92% |
| Other Changes | CN¥89.93 Million | +7.95% |
| Total Change | CN¥- | 7.55% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Dayang Biotech Group Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.57x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.54x to 1.57x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥3.83 | CN¥21.19 | x |
| 2014-12-31 | CN¥4.20 | CN¥21.19 | x |
| 2015-12-31 | CN¥4.35 | CN¥21.19 | x |
| 2016-12-31 | CN¥4.89 | CN¥21.19 | x |
| 2017-12-31 | CN¥6.24 | CN¥21.19 | x |
| 2018-12-31 | CN¥7.51 | CN¥21.19 | x |
| 2019-12-31 | CN¥7.92 | CN¥21.19 | x |
| 2020-12-31 | CN¥14.42 | CN¥21.19 | x |
| 2021-12-31 | CN¥11.79 | CN¥21.19 | x |
| 2022-12-31 | CN¥12.08 | CN¥21.19 | x |
| 2023-12-31 | CN¥12.49 | CN¥21.19 | x |
| 2024-12-31 | CN¥12.83 | CN¥21.19 | x |
| 2025-12-31 | CN¥13.47 | CN¥21.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Dayang Biotech Group Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.82%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.55%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.61x
- Recent ROE (8.82%) is below the historical average (11.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 14.93% | 5.27% | 1.13x | 2.50x | CN¥8.70 Million |
| 2014 | 14.45% | 6.12% | 0.99x | 2.39x | CN¥8.65 Million |
| 2015 | 11.83% | 5.28% | 0.98x | 2.29x | CN¥3.66 Million |
| 2016 | 12.57% | 6.53% | 0.95x | 2.04x | CN¥5.89 Million |
| 2017 | 14.88% | 9.06% | 1.08x | 1.52x | CN¥16.48 Million |
| 2018 | 16.07% | 12.12% | 0.97x | 1.37x | CN¥26.73 Million |
| 2019 | 15.96% | 12.79% | 0.96x | 1.30x | CN¥29.69 Million |
| 2020 | 9.56% | 13.50% | 0.55x | 1.28x | CN¥-4.21 Million |
| 2021 | 7.07% | 8.94% | 0.57x | 1.39x | CN¥-29.06 Million |
| 2022 | 8.20% | 7.63% | 0.70x | 1.53x | CN¥-17.78 Million |
| 2023 | 4.96% | 5.44% | 0.59x | 1.53x | CN¥-50.81 Million |
| 2024 | 6.06% | 7.01% | 0.55x | 1.57x | CN¥-41.47 Million |
| 2025 | 8.82% | 9.55% | 0.57x | 1.61x | CN¥-13.31 Million |
Industry Comparison
This section compares Zhejiang Dayang Biotech Group Co's net assets metrics with peer companies in the Chemicals industry.
Industry Context
- Industry: Chemicals
- Average net assets among peers: $2,409,096,302
- Average return on equity (ROE) among peers: 6.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Dayang Biotech Group Co (003017) | CN¥1.17 Billion | 14.93% | 0.60x | $312.56 Million |
| North Huajin Chemical Industries Co Ltd (000059) | $7.39 Billion | 0.27% | 3.43x | $1.08 Billion |
| Sichuan Chemical Co Ltd (000155) | $-1.60 Billion | 0.00% | 0.00x | $3.32 Billion |
| Jiangsu Wujiang China Eastern Silk Market Co Ltd (000301) | $2.69 Billion | 5.91% | 0.33x | $11.74 Billion |
| Zangge Holding Co Ltd (000408) | $7.91 Billion | 3.90% | 0.22x | $18.37 Billion |
| Sichuan Jinlu Group Co Ltd (000510) | $451.72 Million | 16.44% | 0.89x | $1.26 Billion |
| Jilin Gpro Titanium Industry Co Ltd (000545) | $1.88 Billion | -7.74% | 0.64x | $366.79 Million |
| Aoyuan Beauty Valley Technology Co Ltd (000615) | $365.16 Million | 13.94% | 0.26x | $829.17 Million |
| Ningxia Younglight Chemicals Co Ltd (000635) | $2.67 Billion | 1.91% | 0.16x | $371.42 Million |
| Maoming Petro-Chemical Shihua Co Ltd (000637) | $132.67 Million | 24.35% | 1.07x | $286.80 Million |
| Inner Mongolia Yuan Xing Energy Co Ltd (000683) | $2.21 Billion | 4.88% | 1.07x | $3.32 Billion |
About Zhejiang Dayang Biotech Group Co
Zhe Jiang Dayang Biotech Group Co., Ltd. operates as a chemical raw material manufacturing company in China and internationally. The company offers inorganic chemicals, including potassium carbonate and chloride, ammonium chloride, and bicarbonate food and feed additives; industrial grade potassium carbonate and bicarbonate; and agricultural and industrial grade ammonium chloride. It also provide… Read more